PropertyValue
?:abstract
  • Individuals with chronic obstructive pulmonary disease (COPD) have long been identified to have an elevated serum level of angiotensin‐converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The newest discoveries by Higham et al. (1) were the increased ACE2 expression in the bronchial epithelium of overweight COPD patients compared to their non‐overweight counterparts.
?:creator
?:doi
  • 10.1002/oby.22976
?:doi
?:journal
  • Obesity_(Silver_Spring)
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/5eafce22d6c45a5341df22f5677b690e6fe0046d.json
?:pmcid
?:pmid
?:pmid
  • 32692903.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • The potential benefit of telmisartan to protect overweight COPD patients from the acquisition of COVID‐19
?:type
?:year
  • 2020-07-21

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/cvce4gtl>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/cvce4gtl>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all